----
Current ValuationThe current P/E ratio is -14.12, above the reasonable range, cheaper than 7.94% of the time in the past 1 years, and the industry ranks 198/256, the industry Median -1.13.
-14.12xP/E
$1.94Stock price
$-0.14Earnings per share
-14.12xP/E
Stock price$1.94Earnings per share$-0.14
Historical Valuation
P/E ratioTypical rangeMedian
- P/E ratio
- -17.03x
- Typical range
- -27.77x–-14.79x
Peer P/E ratio Comparison
It displays how the company's P/E ratio compares to top companies within its industry.
0295887116
The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.
Industry P/E ratio Comparison
This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x20x40x60x80x100x
| Name/Symbol | |||
|---|---|---|---|
TAKUSTakeda Pharmaceutical Company | -61.57x | 154.30% | $64.32B |
BAYRYUSBayer | -24.19x | -- | $48.73B |
BAYZFUSBayer Aktiengesellschaft | -24.08x | -- | $48.51B |
VTRSUSViatris | -51.68x | 107.68% | $21.23B |
ELANUSElanco Animal Health | -56.97x | 129.36% | $11.34B |
AXSMUSAxsome Therap | -42.66x | 21.12% | $8.18B |
VREOFUSVIREO GROWTH INC | -120.44x | -- | $8.08B |
CURLFUSCuraleaf Holdings, Inc. | -119.47x | -- | $6.22B |
BLTEUSBelite Bio | -59.12x | 29.87% | $6.05B |
MANEUSVeraDermics | -55.48x | 97.44% | $5.79B |
RGCUSRegencell Bioscience | -415.37x | -- | $4.86B |
DFTXUSDefinium Therapeutics | -13.67x | 54.55% | $4.84B |
EWTXUSEdgewise Therapeutics | -22.02x | 207.38% | $4.34B |
AMLXUSAmylyx Pharmaceuticals | -23.58x | 1.76% | $3.59B |
TARSUSTarsus Pharmaceuticals | -68.06x | 256.39% | $3.16B |
ELVNUSEnliven Therapeutics | -29.00x | 5.59% | $3.07B |
SUPNUSSupernus Pharma | -22.25x | 66.18% | $2.45B |
MBXUSMBX Biosciences | -23.30x | 31.12% | $2.43B |
BHCUSBausch Health | -2.21x | 569.84% | $2.43B |
PRGOUSPerrigo | -1.31x | 100.10% | $2.27B |
Risk Warning
Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.
